N/A
N=53
Natural History Study in Subjects With Usher Syndrome
Usher Syndrome, Type 1B
Bottom Line
View on ClinicalTrials.gov: NCT03814499 ↗Enrolled (actual)
53
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: BCVA - Better Seeing Eyes — -2.26 ETDRS score — p=<0.01
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult · 8+ yrs
- Sex
- All
- Sponsor
- Fondazione Telethon
- Primary completion
- Dec 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY BCVA - Better Seeing Eyes |
-1.468 | <0.01 sig |
| PRIMARY BCVA - Better Seeing Eyes |
-1.468 | <0.01 sig |
| PRIMARY III4e Area - Better Seeing Eyes |
70.286 | 0.4265 |
| PRIMARY III4e Area - Better Seeing Eyes |
70.286 | 0.4265 |
| PRIMARY V4e Area - Better Seeing Eyes |
700.245 | 0.2716 |
| PRIMARY V4e Area - Better Seeing Eyes |
700.245 | 0.2716 |
| PRIMARY BCVA - Worse Seeing Eyes |
-0.909 | 0.2677 |
| PRIMARY BCVA - Worse Seeing Eyes |
-0.909 | 0.2677 |
| PRIMARY III4e Area - Worse Seeing Eyes |
-407.928 | 0.1124 |
| PRIMARY III4e Area - Worse Seeing Eyes |
-407.928 | 0.1124 |
| PRIMARY V4e Area - Worse Seeing Eyes |
610.017 | 0.216 |
| PRIMARY V4e Area - Worse Seeing Eyes |
610.017 | 0.216 |
| SECONDARY MS - Better Seeing Eyes |
-0.315 | 0.7889 |
| SECONDARY MS - Better Seeing Eyes |
-0.315 | 0.7889 |
| SECONDARY CMT - Better Seeing Eyes |
-5.667 | 0.5092 |
| SECONDARY CMT - Better Seeing Eyes |
-5.667 | 0.5092 |
| SECONDARY EZ Band Horizontal - Better Seeing Eyes |
-160.556 | 0.0677 |
| SECONDARY EZ Band Horizontal - Better Seeing Eyes |
-160.556 | 0.0677 |
| SECONDARY EZ Band Vertical - Better Seeing Eyes |
190.553 | 0.3148 |
| SECONDARY EZ Band Vertical - Better Seeing Eyes |
190.553 | 0.3148 |
| SECONDARY MS - Worse Seeing Eyes |
-0.758 | 0.7196 |
| SECONDARY MS - Worse Seeing Eyes |
-0.758 | 0.7196 |
| SECONDARY CMT - Worse Seeing Eyes |
-2.026 | 0.4224 |
| SECONDARY CMT - Worse Seeing Eyes |
-2.026 | 0.4224 |
| SECONDARY EZ Band Horizontal - Worse Seeing Eyes |
-21.658 | 0.1461 |
| SECONDARY EZ Band Horizontal - Worse Seeing Eyes |
-21.658 | 0.1461 |
| SECONDARY EZ Band Vertical - Worse Seeing Eyes |
-15.861 | 0.0901 |
| SECONDARY EZ Band Vertical - Worse Seeing Eyes |
-15.861 | 0.0901 |
Summary
Natural History Study in Subjects With Usher Syndrome ((USH1B) is a multi-centre, longitudinal, observational study designed to evaluate disease progression in subjects with USH1B by several vision-related assessments.
Eligibility Criteria
Inclusion Criteria
- Must be willing to adhere to protocol for long-term follow-up as evidenced by written informed consent or parental permission and subject assent.
- Subjects diagnosed with USH1.
- Molecular diagnosis of USH1B due to MYO7A mutations (homozygotes or compound heterozygotes).
- Age eight years old or older at the time of baseline.
- Visual acuity ≥ 20/640 in at least one eye
Exclusion Criteria
- Unable or unwilling to meet requirements of the study.
- Unable to communicate with suitable verbal/auditory and/or tactile sign language (in the opinion of the investigator)
- Participation in a clinical study with an investigational drug in the past six months.
- Pre-existing eye conditions that would interfere with the interpretation of study endpoints (for example, glaucoma, corneal or significant lenticular opacities, cystoid macular oedema, macular hole).
- Complicating systemic diseases in which the disease itself, or the treatment for the disease, can alter ocular function. Examples are malignancies whose treatment could affect central nervous system function (for example, radiation treatment of the orbit; leukemia with CNS/optic nerve involvement). Also excluded would be subjects with immuno- compromising diseases, as there could be susceptibility to opportunistic infection [such as cytomegalovirus (CMV) retinitis].
- Subjects with diabetes or sickle cell disease would be excluded if they had any manifestation of advanced retinopathy (e.g. macular edema or proliferative changes).
- Prior ocular surgery within three months.
- Any other condition that would not allow the potential subject to complete follow-up examinations during the course of the study and, in the opinion of the investigator, makes the potential subject unsuitable for the study.
Data sourced from ClinicalTrials.gov (NCT03814499). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.